Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jan 11

PMID 35008392

Authors

Ramya Ambur Sankaranarayanan

Jennifer Peil

Andreas T J Vogg

Carsten Bolm

Steven Terhorst

Arno Classen

Matthias Bauwens

Jochen Maurer

Felix Mottaghy

Agnieszka Morgenroth

Affiliations

Soon will be listed here.

Abstract

PARP1 inhibitors (PARPi) are currently approved for BRCA metastatic breast cancer, but they have shown limited response in triple negative breast cancer (TNBC) patients. Combination of an Auger emitter with PARPis enables PARP inhibition and DNA strand break induction simultaneously. This will enhance cytotoxicity and additionally allow a theranostic approach. This study presents the radiosynthesis of the Auger emitter [I] coupled olaparib derivative: [I]-PARPi-01, and its therapeutic evaluation in a panel of TNBC cell lines. Specificity was tested by a blocking assay. DNA strand break induction was analysed by γH2AX immunofluorescence staining. Cell cycle analysis and apoptosis assays were studied using flow cytometry in TNBC cell lines (BRCA). Anchorage independent growth potential was evaluated using soft agar assay. [I]-PARPi-01 showed PARP1-specificity and higher cytotoxicity than olaparib in TNBC cell lines irrespective of BRCA their status. Cell lines harbouring DNA repair deficiency showed response to [I]-PARPi-01 monotherapy. Combined treatment with Dox-NP further enhanced therapeutic efficiency in metastatic resistant BRCA cell lines. The clonogenic survival was significantly reduced after treatment with [I]-PARPi-01 in all TNBC lines investigated. Therapeutic efficacy was further enhanced after combined treatment with chemotherapeutics. [I]-PARPi-01 is a promising radiotherapeutic agent for low radiation dosages, and mono/combined therapies of TNBC.

Citing Articles

Currents status of radiotracers for breast cancer imaging in PET.

Jean C, Roux S, Aziz A, Mocquery-Corre M, Bazzi R, Merrouche Y Transl Oncol. 2025; 53:102304.

PMID: 39922049 PMC: 11849122. DOI: 10.1016/j.tranon.2025.102304.

[F]F-Poly(ADP-Ribose) Polymerase Inhibitor Radiotracers for Imaging PARP Expression and Their Potential Clinical Applications in Oncology.

Ndlovu H, Lawal I, Mdanda S, Kgatle M, Mokoala K, Al-Ibraheem A J Clin Med. 2024; 13(12).

PMID: 38929955 PMC: 11204862. DOI: 10.3390/jcm13123426.

Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.

Zhang Y, Liang L, Li Z, Huang Y, Jiang M, Zou B Front Oncol. 2023; 13:1295579.

PMID: 38111536 PMC: 10726039. DOI: 10.3389/fonc.2023.1295579.

DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy.

Obata H, Ogawa M, Zalutsky M Pharmaceutics. 2023; 15(7).

PMID: 37514113 PMC: 10384049. DOI: 10.3390/pharmaceutics15071926.

Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer.

Hoffman S, Mixdorf J, Kwon O, Johnson T, Makvandi M, Lee H Nucl Med Biol. 2023; 122-123:108368.

PMID: 37490805 PMC: 10529069. DOI: 10.1016/j.nucmedbio.2023.108368.

References

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

Gu Y, Wang C, Zhu R, Yang J, Yuan W, Zhu Y . The cancer-testis gene, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency. Cancer Biol Med. 2021; 18(1):74-87. PMC: 7877187. DOI: 10.20892/j.issn.2095-3941.2020.0071. View

Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

Chalakur-Ramireddy N, Pakala S . Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. Biosci Rep. 2018; 38(1). PMC: 5789156. DOI: 10.1042/BSR20171357. View

Wilson T, Jannetti S, Guru N, Pillarsetty N, Reiner T, Pirovano G . Improved radiosynthesis of I-MAPi, an auger theranostic agent. Int J Radiat Biol. 2020; 99(1):70-76. PMC: 7775866. DOI: 10.1080/09553002.2020.1781283. View

Ku A, Facca V, Cai Z, Reilly R . Auger electrons for cancer therapy - a review. EJNMMI Radiopharm Chem. 2019; 4(1):27. PMC: 6800417. DOI: 10.1186/s41181-019-0075-2. View

Gu Y, Helenius M, Vaananen K, Bulanova D, Saarela J, Sokolenko A . BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine. Sci Rep. 2016; 6:28217. PMC: 4911578. DOI: 10.1038/srep28217. View

Bardia A, Mayer I, Vahdat L, Tolaney S, Isakoff S, Diamond J . Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019; 380(8):741-751. DOI: 10.1056/NEJMoa1814213. View

Birkbak N, Wang Z, Kim J, Eklund A, Li Q, Tian R . Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012; 2(4):366-375. PMC: 3806629. DOI: 10.1158/2159-8290.CD-11-0206. View

10.

Robson M, Im S, Senkus E, Xu B, Domchek S, Masuda N . Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017; 377(6):523-533. DOI: 10.1056/NEJMoa1706450. View

11.

Litton J, Rugo H, Ettl J, Hurvitz S, Goncalves A, Lee K . Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018; 379(8):753-763. PMC: 10600918. DOI: 10.1056/NEJMoa1802905. View

12.

Wojdacz T, Dobrovic A . Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007; 35(6):e41. PMC: 1874596. DOI: 10.1093/nar/gkm013. View

13.

Holme H, Gulati A, Brough R, Fleuren E, Bajrami I, Campbell J . Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Sci Rep. 2018; 8(1):10614. PMC: 6045584. DOI: 10.1038/s41598-018-29043-z. View

14.

Osytek K, Blower P, Costa I, Smith G, Abbate V, Terry S . In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-201. EJNMMI Res. 2021; 11(1):63. PMC: 8257813. DOI: 10.1186/s13550-021-00802-w. View

15.

Xiao G, Lundine D, Annor G, Canar J, Ellison V, Polotskaia A . Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2019; 80(3):394-405. PMC: 7002183. DOI: 10.1158/0008-5472.CAN-19-1036. View

16.

Wu X, Zahari M, Renuse S, Kelkar D, Barbhuiya M, Rojas P . The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. Oncotarget. 2016; 8(2):2971-2983. PMC: 5356856. DOI: 10.18632/oncotarget.13579. View

17.

Beniey M, Haque T, Hassan S . Translating the role of PARP inhibitors in triple-negative breast cancer. Oncoscience. 2019; 6(1-2):287-288. PMC: 6382255. DOI: 10.18632/oncoscience.474. View

18.

Patra S, Young V, Llewellyn L, Senapati J, Mathew J . BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model. Asian Pac J Cancer Prev. 2017; 18(8):2209-2213. PMC: 5697482. DOI: 10.22034/APJCP.2017.18.8.2209. View

19.

Minami A, Nakanishi A, Ogura Y, Kitagishi Y, Matsuda S . Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair. Front Oncol. 2014; 4:318. PMC: 4226230. DOI: 10.3389/fonc.2014.00318. View

20.

Wesierska-Gadek J, Mauritz M, Mitulovic G, Cupo M . Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells. J Cell Biochem. 2015; 116(12):2824-39. DOI: 10.1002/jcb.25229. View